Overview

Asciminib Roll-over Study

Status:
Not yet recruiting

Trial end date:
2026-07-10

Target enrollment:

Participant gender:

Summary

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Imatinib Mesylate
Niacinamide